GlassScriptPhysician profile
Erin S Koepplinger
NPI 1841629011
$9,867.31
in general payments reported to CMS, 2019-2025
27 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,046 · 2022: $2,373 · 2023: $1,437 · 2024: $1,810 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,175 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,175.11 |
| Education | $273.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,901.56 | 2021-2025 | Tremfya, Remicade, Simponi |
| Abbvie INC. | $1,421.93 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,284.93 | 2021-2025 | |
| Genzyme Corporation | $806.31 | 2021-2025 | |
| Ucb, INC. | $534.00 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $449.80 | 2021-2024 | Siliq, Targretin |
| Pfizer INC. | $407.87 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $393.31 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $380.75 | 2021-2025 | |
| Lilly USA, LLC | $365.28 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $304.81 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $289.88 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $286.12 | 2021-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.73 | 2022-2025 | Spevigo, Cyltezo |
| Leo Pharma INC. | $160.66 | 2021-2025 | Anzupgo, Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $126.75 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $86.74 | 2023-2024 | Vtama |
| Organon LLC | $84.47 | 2025 | Vtama |
| Journey Medical Corporation | $77.13 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Biofrontera INC. | $59.76 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $37.20 | 2022 | |
| Vyne Pharmaceuticals INC. | $26.06 | 2021 | |
| Fresenius Kabi USA, LLC | $24.82 | 2023 | Idacio |
| Galderma Laboratories, L.P. | $21.52 | 2024 | Aklief |
| Paratek Pharmaceuticals, INC. | $20.70 | 2022 | |
| Botanix Sb INC | $19.23 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Koepplinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.